Publicacions en què col·labora amb Rafael Sirera Pérez (14)

2023

  1. Circulating Immune Proteins: Improving the Diagnosis and Clinical Outcome in Advanced Non-Small Cell Lung Cancer

    International Journal of Molecular Sciences, Vol. 24, Núm. 24

2021

  1. Analysis of the gut microbiota: An emerging source of biomarkers for immune checkpoint blockade therapy in non-small cell lung cancer

    Cancers, Vol. 13, Núm. 11

  2. Characterization of circulating t cell receptor repertoire provides information about clinical outcome after pd-1 blockade in advanced non-small cell lung cancer patients

    Cancers, Vol. 13, Núm. 12

  3. dPCR application in liquid biopsies: divide and conquer

    Expert Review of Molecular Diagnostics, Vol. 21, Núm. 1, pp. 3-15

2020

  1. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer

    Expert Review of Molecular Diagnostics, Vol. 20, Núm. 6, pp. 575-582

  2. CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer

    Translational Lung Cancer Research, Vol. 9, Núm. 4, pp. 1074-1083

2019

  1. Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer

    Cell Death and Disease, Vol. 10, Núm. 9

2018

  1. EpCAM duality becomes this molecule in a new Dr. Jekyll and Mr. Hyde tale

    Critical Reviews in Oncology/Hematology, Vol. 126, pp. 52-63

2017

  1. Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients

    OncoImmunology, Vol. 6, Núm. 1

  2. MicroRNA profiling associated with non-small cell lung cancer: Next generation sequencing detection, experimental validation, and prognostic value

    Oncotarget, Vol. 8, Núm. 34, pp. 56143-56157

  3. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer

    Expert Review of Molecular Diagnostics, Vol. 17, Núm. 3, pp. 209-215

2016

  1. Analysis of the immune microenvironment in resected non-small cell lung cancer: The prognostic value of different T lymphocyte markers

    Oncotarget, Vol. 7, Núm. 33, pp. 52849-52861

2014

  1. A gene signature combining the tissue expression of three angiogenic factors is a prognostic marker in early-stage non-small cell lung cancer

    Annals of Surgical Oncology, Vol. 21, Núm. 2, pp. 612-620

2006

  1. Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications

    Lung Cancer, Vol. 52, Núm. 3, pp. 343-347